Kanamycin

Generic Name: Kanamycin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₆N_₄O_₁₁

CAS Number: 59-01-8

Unique Ingredient Identifier: EQK9Q303C5

Background: Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.

Indication: For treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.

Associated Conditions: Bacterial Infection caused by Acinetobacter species, Bacterial Infection caused by E. coli, Bacterial Infection caused by Enterobacter aerogenes, Bacterial Infection caused by Klebsiella Pneumoniae, Bacterial Infection caused by Proteus species, Bacterial Infection caused by Serratia marcescens

Associated Therapies: -

Clinical Trials

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis
Multidrug Resistant Tuberculosis
Extensively-drug Resistant Tuberculosis

Interventions: Drug: Pyrazinamide
Drug: Linezolid
Drug: Ethionamide
Drug: Bedaquiline
Drug: Terizidone
Drug: Levofloxacin
Drug: Moxifloxacin
Drug: Kanamycin
Drug: Isoniazid

First Posted Date: 2015-05-27

Last Posted Date: 2021-09-29

Lead Sponsor: University of Cape Town

Target Recruit Count: 154

Registration Number: NCT02454205

Locations: 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Phase 3

Completed

Conditions: MDR-TB

Interventions: Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
Drug: Moxifloxacin
Drug: Clofazimine
Drug: Ethambutol
Drug: Pyrazinamide
Drug: Isoniazid
Drug: Prothionamide
Drug: Bedaquiline
Drug: Kanamycin
Drug: Levofloxacin

First Posted Date: 2015-04-06

Last Posted Date: 2023-09-28

Lead Sponsor: IUATLD, Inc

Target Recruit Count: 588

Registration Number: NCT02409290

Locations: 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹
St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪
JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

and more 10 locations

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Kanamycin
Drug: Moxifloxacin

First Posted Date: 2009-01-01

Last Posted Date: 2019-12-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 19

Registration Number: NCT00816426

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷
National Medical Center, Seoul, Korea, Republic of

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed

Conditions: HIV Infections

Interventions: Drug: darunavir/ritonavir dosage #1
Drug: TAF w/cobicistat
Drug: TAF w/cobicistat or ritonavir
Drug: tenofovir alafenamide fumarate (TAF)
Drug: elvitegravir/cobicistat
Drug: darunavir/cobicistat
Drug: atazanavir/cobicistat
Drug: lopinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir/tenofovir dosage #1
Drug: lopinavir/ritonavir dosage #2
Drug: indinavir/ritonavir dosage #1
Drug: fosamprenavir/ritonavir
Drug: atazanavir/ritonavir dosage #1
Drug: didanosine delayed release (Videx® EC)
Drug: emtricitabine
Drug: nelfinavir dosage #1
Drug: tipranavir/ritonavir
Drug: etravirine
Drug: darunavir/ritonavir dosage #4
Drug: indinavir/ritonavir dosage #2
Drug: rilpivirine
Drug: ethambutol
Drug: efavirenz
Drug: raltegravir
Drug: dolutegravir
Drug: kanamycin
Drug: nevirapine
Drug: amprenavir
Drug: abacavir
Drug: tenofovir
Drug: maraviroc
Drug: darunavir/ritonavir dosage #2
Drug: lopinavir/ritonavir dosage #3
Drug: lopinavir/ritonavir dosage #4
Drug: tenofovir/atazanavir/ritonavir dosage #2
Drug: atazanavir/ritonavir dosage #2
Drug: nelfinavir dosage #2
Drug: rifampicin
Drug: amikacin
Drug: darunavir/ritonavir dosage #3
Drug: etonogestrel implant
Drug: capreomycin
Drug: ethinyl estradiol
Drug: isoniazid
Drug: moxifloxacin
Drug: levoflaxacin
Drug: pyrazinamide
Drug: ofloxacin
Drug: ethionamide/prothionamide
Drug: terizidone/cycloserine
Drug: para-aminosalicylic acid (PAS)
Drug: high dose INH
Drug: bedaquiline
Drug: clofazamine
Drug: delamanid
Drug: linezolid
Drug: pretomanid

First Posted Date: 2002-08-01

Last Posted Date: 2022-07-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1578

Registration Number: NCT00042289

Locations: 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦
Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸
Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States

and more 59 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy